Bookmark

Add to MyYahoo RSS

Bristol-Myers Squibb News

News on Bristol-Myers Squibb continually updated from thousands of sources around the net.

Thursday Jul 10 | The Motley Fool

Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan .

Comment?

Related Topix: Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Pharmaceuticals, Allergan, Biotech

Thursday Jul 10 | Pharmaceutical Processing

Bristol-Myers Squibb Makes Plans to Submit Biologics License Application for OpdivoA

Bristol-Myers Squibb Company today announced that, following discussions with the U.S. Food and Drug Administration , the company is planning a third quarter submission of a Biologics Licensing Application for OpdivoA for previously treated advanced melanoma.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals, Healthcare Law, Law

Tue Jul 08, 2014

AmericanBankingNews.com

Bristol-Myers Squibb Given New $55.00 Price Target at Leerink Swann

Leerink Swann's price objective would suggest a potential upside of 14.92% from the stock's previous close.

Comment?

Related Topix: Bristol Myers Squibb, Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Media, Publishing, Medarex, Pharmaceuticals

Mon Jul 07, 2014

Information Technology

Japan Approves First All-Oral, Interferon- and Ribavirin-Free...

Bristol-Myers Squibb Company announced today that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , and Sunvepra , a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Hepatitis, Health, Pharmaceuticals

Health Data Management

Duke, Bristol-Myers Squibb Open Up Study Data

These areas, it says, will refine ICD-10 plans to minimize impacts on productivity and reimbursement.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry

Thu Jul 03, 2014

Seeking Alpha

Bristol-Myers Squibb May Be Fast-Tracking Its Promising Cancer Drug

However, with the recent release of promising data and the early termination of the first batch of Phase 3 trials, the drug may hit the market sooner than expected.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry, Oncology

Wed Jul 02, 2014

In-PharmaTechnologist.com

B-MS recalls CMO made injectable blood thinner after finding "visible particles"

Bristol Myers Squibb has recalled several batches of the injectable version of the blood thinner Coumadin made by its CMO, Pharmalucence.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry, Bedford, MA

Tue Jul 01, 2014

The Jersey Journal

Strong-smelling fertilizer spills in Hopewell Twp., closes roads for an hour

HOPEWELL TOWNSHIP - An unknown liquid with a strong odor spilled on Titus Mill Road and brought out emergency personnel from four agencies, forced the closure of the rear entrance to a business and for a short while closed an intersection, police said today.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry

CiteULike

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly...

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial Abstract 3770[IMG] /medium/permbld2011abs03.gif" ALT="Formula "> BackgroundSecond generation tyrosine kinase inhibitors such as ... (more)

Comment?

Related Topix: Leukemia, Health, Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry

Mon Jun 30, 2014

Pharmaceutical Processing

BMS Issues Voluntary Nationwide Recall of COUMADINA for Injection...

Bristol-Myers Squibb Company is voluntarily recalling six lots of COUMADINA FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Coumadin, Warfarin (generic), Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals

Fri Jun 27, 2014

Seeking Alpha

Bristol-Myers Squibb: Expect Accelerated Dividend Growth In The Near Term

The dividend of Bristol-Myers Squibb has only grown by a 3% CAGR since 2010. In my view, there is a good chance that the dividend growth may accelerate to about 5% per annum in the near term.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Pharmaceuticals, Healthcare Industry

Freshnews

Bristol-Myers Squibb Receives Positive CHMP Opinion for DaklinzaA ...

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Daklinza , an investigational, potent pan-genotypic NS5A complex inhibitor , be granted approval for use in combination with other medicinal products for the treatment ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Hepatitis, Health, Marketing, Opinion

Wed Jun 25, 2014

TheStreet.com

Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals, Mozilla

TheStreet.com

Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today

The biopharmaceutical company ended trials after test results revealed that patients treated with Bristol-Meyers melanoma drugs had a "superior overall survival" rate than patients treated with only chemotherapy.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals, Financial Markets

Tue Jun 24, 2014

Freshnews

Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational...

Bristol-Myers Squibb Company today announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent Data Monitoring Committee showed evidence of superior overall survival in ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals

BioSpace

Bristol-Myers Squibb Company Ties It Up With Duke University In Bid...

InVivo Therapeutics is axing jobs but others are hiring too! Check it out! Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute NEW YORK-- --Bristol-Myers Squibb today announced a collaboration with Duke University through its Duke Clinical Research Institute focused on clinical trial ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Duke University, Healthcare Law, Law, Food and Drug Administration, Marketing

Mon Jun 23, 2014

Medical Daily

Hepatitis Cure In 4 Weeks? Bristol-Myers Combination Pill With Sovaldi May Do The Trick

Pharmaceutical company Bristol-Myers Squibb is planning on testing a three-drug combo Hepatitis C pill with Gilead's breakthrough Sovaldi, in hopes of curing Hepatitis C in just one month.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Bristol Myers Squibb, Healthcare Industry, Gilead Sciences, Bloomsbury Publishing, Publishing, Media, Pharmaceuticals

Sun Jun 22, 2014

Iol.co.za

AbbVie tables $46.5bn takeover offer for Shire

ABBVIE revealed a $46.5 billion takeover bid for Shire last week in the first public acquisition approach for the specialty drugmaker after years of takeover speculation.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pharmaceuticals

•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••